Table 3. Effects of ALDH2 polymorphisms on urinary excretion of styrene specific metabolites and the levels of various parameters of genetic damage in control and styrene-exposed workers.
| Group | ALDH2 genotypes | Urinary MA+PGA (mg/g creatinine) | Urinary 8-OH-dG (ng/mg creatinine) | Tail Intensity | Net Fpg DNA damage | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. | Mean ± SD | P-value | No. | Mean ± SD | P-value | No. | Mean ± SD | P-value | No. | Mean ± SD | P-value | ||
| Control | ALDH2 1*/1* | n.d | 94 | 3.88 ± 1.41 | - | 96 | 11.42 ± 4.05 | - | 96 | 5.91 ± 1.98 | - | ||
| ALDH2 1*/2* | n.d | 42 | 3.91 ± 1.47 | 8.88E-01 | 43 | 12.04 ± 3.57 | 3.71E-01 | 43 | 6.38 ± 1.88 | 1.88E-01 | |||
| ALDH2 2*/2* | n.d | 5 | 3.74 ± 0.77 | 7.30E-01 | 6 | 13.93 ± 2.81 | 8.30E-02 | 6 | 6.68 ± 0.91 | 1.05E-01 | |||
| ALDH2 1*/2*+2*/2* | n.d | 47 | 3.89 ± 1.41 | 9.38E-01 | 49 | 12.27 ± 3.52 | 1.96E-01 | 49 | 6.41 ± 1.79 | 1.25E-01 | |||
| Workplace A | ALDH2 1*/1* | 78 | 86.94 ± 181.02 | - | 78 | 4.50 ± 1.69 | - | 83 | 12.32 ± 3.75 | - | 83 | 6.63 ± 2.26 | - |
| ALDH2 1*/2* | 30 | 41.56 ± 46.57 | 4.35E-02* | 30 | 4.38 ± 1.53 | 7.24E-01 | 31 | 13.87 ± 3.65 | 4.92E-02* | 31 | 6.85 ± 2.09 | 6.18E-01 | |
| ALDH2 2*/2* | 4 | 36.35 ± 32.46 | 6.85E-02 | 5 | 5.13 ± 0.88 | 1.95E-01 | 5 | 15.39 ± 2.26 | 3.44E-02* | 5 | 7.11 ± 1.60 | 5.51E-01 | |
| ALDH2 1*/2*+2*/2* | 34 | 40.94 ± 44.77 | 3.82E-02* | 35 | 4.49 ± 1.47 | 9.69E-01 | 36 | 14.08 ± 3.50 | 1.58E-02* | 36 | 6.89 ± 2.01 | 5.32E-01 | |
| Workplace B | ALDH2 1*/1* | 83 | 99.60 ± 161.81 | - | 80 | 4.36 ± 1.47 | - | 83 | 12.58 ± 3.05 | - | 83 | 6.52 ± 2.28 | - |
| ALDH2 1*/2* | 29 | 60.22 ± 123.74 | 1.80E-01 | 29 | 5.63 ± 2.94 | 3.30E-02* | 29 | 14.16 ± 3.36 | 3.06E-02* | 29 | 7.61 ± 2.36 | 3.58E-02* | |
| ALDH2 2*/2* | 2 | 15.29 ± 2.84 | 9.57E-06*** | 2 | 5.46 ± 0.04 | 4.71E-09*** | 2 | 15.14 ± 1.43 | 2.11E-01 | 2 | 9.55 ± 1.62 | 2.16E-01 | |
| ALDH2 1*/2*+2*/2* | 31 | 57.32 ± 120.07 | 1.35E-01 | 31 | 5.62 ± 2.84 | 2.45E-02* | 31 | 14.22 ± 3.27 | 1.85E-02* | 31 | 7.74 ± 2.35 | 1.64E-02* | |
| Workplace C | ALDH2 1*/1* | 63 | 135.35 ± 144.31 | - | 63 | 5.55 ± 1.87 | - | 63 | 13.10 ± 2.63 | - | 63 | 7.10 ± 2.06 | - |
| ALDH2 1*/2* | 27 | 88.69 ± 70.02 | 4.22E-02* | 26 | 6.83 ± 2.32 | 1.64E-02* | 29 | 15.62 ± 2.66 | 8.82E-05*** | 29 | 8.36 ± 2.05 | 8.06E-03** | |
| ALDH2 2*/2* | 2 | 42.85 ± 3.30 | 4.09E-06*** | 2 | 7.63 ± 1.36 | 2.60E-01 | 2 | 18.17 ± 1.50 | 1.05E-01 | 2 | 10.16 ± 0.98 | 1.06E-01 | |
| ALDH2 1*/2*+2*/2* | 29 | 85.53 ± 68.50 | 2.72E-02* | 28 | 6.89 ± 2.26 | 8.52E-03** | 31 | 15.79 ± 2.66 | 2.14E-05*** | 31 | 8.48 ± 2.04 | 3.10E-03** | |
| All exposed | ALDH2 1*/1* | 224 | 105.25 ± 164.67 | - | 221 | 4.75 ± 1.74 | - | 229 | 12.63 ± 3.22 | - | 229 | 6.72 ± 2.21 | - |
| ALDH2 1*/2* | 86 | 62.65 ± 87.51 | 3.57E-03** | 85 | 5.55 ± 2.51 | 7.33E-03** | 89 | 14.54 ± 3.31 | 7.07E-06*** | 89 | 7.59 ± 2.23 | 2.00E-03** | |
| ALDH2 2*/2* | 8 | 32.71 ± 24.04 | 4.20E-06*** | 9 | 5.76 ± 1.33 | 5.31E-02* | 9 | 15.95 ± 2.17 | 1.50E-03** | 9 | 8.33 ± 1.97 | 4.04E-02* | |
| ALDH2 1*/2*+2*/2* | 94 | 60.10 ± 84.34 | 1.43E-03** | 94 | 5.57 ± 2.42 | 3.14E-03** | 98 | 14.67 ± 3.24 | 4.86E-07*** | 98 | 7.66 ± 2.21 | 5.28E-04*** | |
*
p < 0.05,
**
p < 0.01,
***
p < 0.001, based on independent samples t - test, and compared with the corresponding wild-type genotype. Data are expressed as mean ± S.E. n.d.: not detectable.